01.12.2023 • News

Elementis Plans New R&D Unit in Portugal

UK’s Elementis, a global specialty chemicals company, will be opening a new unit in Portugal, featuring a center of excellence and R&D laboratory. The new unit, which will be headquartered in Porto and is scheduled to open in the first half of 2024, will support the company’s business segments Personal Care and Performance Specialties and also reinforce the current R&D capacity of the Elementis' laboratories in Asia and the Americas.

As part of this investment, the company plans to hire 100 employees.

By the end of 2024, Elementis expects to invest up to €3 million in Portugal to open the new unit, in addition to the expected annual investment of up to €6 million in people, facilities and laboratories.

The reasons to choose Porto, Elementis said, were mainly the high quality of talent, the business environment beneficial to the company’s objectives and the infrastructure available in the city.

In Porto, Elementis has also identified important opportunities for collaboration, including potential partnerships with institutions like Universidade Católica do Porto, through the Centre of Biotechnology and Fine Chemistry (CBQF) from the Superior School of Biotechnology.

"Elementis’ new location in Porto will be an open and inspiring space for our employees and customers to collaborate on practical demonstrations, presentations and training. We have ambitious plans to launch more than 50 new products by 2026, and this new location will play a crucial role in realizing those plans," said Paul Waterman, CEO of Elementis.

© Matej Kastelic/Shutterstock
© Matej Kastelic/Shutterstock

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.